# Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/reduction-in-recombinant-human-erythropoietin-doses-by-the-use-of-chronic/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Steven Fishbane,Gill L. Frei,John K. Maesaka |
| Citations | 377 |
| DOI | 10.1016/0272-6386(95)90151-5 |
| Fields | Medicine |
| Open Access | true |
| OA Status | hybrid |
| OA URL | https://doi.org/10.1016/0272-6386(95)90151-5 |
| OpenAlex ID | https://openalex.org/W1988500755 |
| PMID | 7611266 |
| Type | article |
| Year | 1995 |

## Paper authors

- [Steven Fishbane](https://scholariq.org/researchers/steven-fishbane/)
- [John K. Maesaka](https://scholariq.org/researchers/john-k-maesaka/)

## Paper journal

- [American Journal of Kidney Diseases](https://scholariq.org/journals/american-journal-of-kidney-diseases/)

## Paper primary topic

- [Erythropoietin and Anemia Treatment](https://scholariq.org/topics/erythropoietin-and-anemia-treatment/)

## Paper topics

- [Erythropoietin and Anemia Treatment](https://scholariq.org/topics/erythropoietin-and-anemia-treatment/)
- [Iron Metabolism and Disorders](https://scholariq.org/topics/iron-metabolism-and-disorders/)
- [Hemoglobinopathies and Related Disorders](https://scholariq.org/topics/hemoglobinopathies-and-related-disorders/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.